ANT3310 / Antabio - LARVOL DELTA

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Antabio

New P1 trial

Evaluation of the activity of the novel antibiotic combination Meropenem-ANT3310 against recent multidrug-resistant Enterobacterales and Acinetobacter baumannii clinical isolates (ESCMID Global 2025) - No abstract available

Clinical • Late-breaking abstract

Pharmacokinetics/pharmacodynamics of ANT3310, in combination with meropenem, against carbapenem-resistant Enterobacterales using a neutropaenic murine acute pyelonephritis model (ESCMID Global 2025) - No abstract available

Combination therapy • PK/PD data • Preclinical • Nephrology

Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem with the diazabyciclooctane beta-lactamase inhibitor ANT3310 (ESCMID Global 2025) - No abstract available

Broad spectrum coverage of serine β-lactamase and high in vitro potency against KPC- and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabyciccloctane β-lactamase inhibitor ANT3310 (ESCMID Global 2025) - No abstract available

Combination therapy • Preclinical

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. (PubMed, Antimicrob Agents Chemother) - "Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Meropenem/ANT3310 (MIC50/MIC90 = 0.5/≥64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC50/MIC90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales."

Journal

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Antabio | Not yet recruiting ➔ Recruiting

Enrollment open • Renal Disease

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Antabio

New P1 trial • Renal Disease

Evaluation of ANT3310 pharmacokinetics-pharmacodynamics, in combination with meropenem, using a dynamic in vitro infection model (ECCMID 2024) - No abstract available

Combination therapy • PK/PD data • Preclinical • Infectious Disease

Spontaneous frequency of resistance to meropenem/ANT3310 in carbapenem-resistant Enterobacterales and Acinetobacter baumannii (ECCMID 2024) - No abstract available

In vitro assessment of the novel antibiotic combination meropenem/ANT3310 against Gram-negative bacteria: CLSI Tier 1 study examining effects of varying MIC parameters and equivalency between agar dilution and broth microdilution methodologies (ECCMID 2024) - No abstract available

Gram negative • Preclinical • Infectious Disease

CLSI M23 tier 2 study to establish broth microdilution quality control ranges for meropenem-ANT3310 (ECCMID 2024) - No abstract available

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ANT3310, a novel serine beta-lactamase inhibitor, in healthy volunteers (ECCMID 2024) - No abstract available

Clinical • PK/PD data

FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Antabio | Recruiting ➔ Completed

Combination therapy • Trial completion

Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. (PubMed, Antimicrob Agents Chemother) - "MEM was poorly active against A. baumannii, as were MEM-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-taniborbactam, cefepime-zidebactam, and imipenem-relebactam (MIC values of ≥32 µg/mL). On the other hand, MEM-ANT3310 displayed an MIC value of 4 µg/mL, similar to that observed with sulbactam-durlobactam, a drug developed to specifically treat A. baumannii infections...Furthermore, MEM-ANT3310 was efficacious in both thigh and lung murine infection models with OXA-23 A. baumannii. This study demonstrates the potent in vitro activity of the MEM-ANT3310 combination against both carbapenem-resistant A. baumannii and Enterobacterales clinical isolates, a key differentiator to other β-lactam/β-lactamase combinations."

Gram negative • Journal • Infectious Disease • Pneumonia

FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Antabio

Combination therapy • New P1 trial